Inovio Pharmaceuticals Inc (NASDAQ: INO) kicked off on Tuesday, up 6.74% from the previous trading day, before settling in for the closing price of $1.93. Over the past 52 weeks, INO has traded in a range of $1.42-$12.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 22.92%. While this was happening, its average annual earnings per share was recorded 47.65%. With a float of $36.39 million, this company’s outstanding shares have now reached $36.67 million.
Let’s determine the extent of company efficiency that accounts for 134 employees. In terms of profitability, gross margin is -636.81%, operating margin of -11541102.4%, and the pretax margin is -20624824.93%.
Inovio Pharmaceuticals Inc (INO) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Inovio Pharmaceuticals Inc is 0.79%, while institutional ownership is 37.18%.
Inovio Pharmaceuticals Inc (INO) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 47.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 39.23% during the next five years compared to 22.92% growth over the previous five years of trading.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Trading Performance Indicators
Take a look at Inovio Pharmaceuticals Inc’s (INO) current performance indicators. Last quarter, stock had a quick ratio of 2.63. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 269.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.19, a number that is poised to hit -0.62 in the next quarter and is forecasted to reach -1.79 in one year’s time.
Technical Analysis of Inovio Pharmaceuticals Inc (INO)
Looking closely at Inovio Pharmaceuticals Inc (NASDAQ: INO), its last 5-days average volume was 0.58 million, which is a drop from its year-to-date volume of 0.74 million. As of the previous 9 days, the stock’s Stochastic %D was 26.92%.
During the past 100 days, Inovio Pharmaceuticals Inc’s (INO) raw stochastic average was set at 69.57%, which indicates a significant increase from 41.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.44% in the past 14 days, which was lower than the 65.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.95, while its 200-day Moving Average is $3.14. However, in the short run, Inovio Pharmaceuticals Inc’s stock first resistance to watch stands at $2.11. Second resistance stands at $2.15. The third major resistance level sits at $2.22. If the price goes on to break the first support level at $1.99, it is likely to go to the next support level at $1.91. Should the price break the second support level, the third support level stands at $1.87.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Key Stats
The company with the Market Capitalisation of 75.55 million has total of 36,674K Shares Outstanding. Its annual sales at the moment are 220 K in contrast with the sum of -107,250 K annual income. Company’s last quarter sales were recorded 70 K and last quarter income was -19,690 K.
